Bausch + Lomb stock draws focus after higher 2026 revenue guidance

Published on 11/12/2026 at 02:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch + Lomb stock is in focus after stronger quarterly earnings and higher 2026 revenue guidance. Profitability remains the key test.

Guidance lifts the investment focus

Bausch + Lomb returned to quarterly profitability while revenue increased year over year.
Management raised its full-year 2026 revenue range, keeping execution and cost control central for investors.
Simply Wall St sees the Vision 27 efficiency program and debt reduction as important factors for the outlook.

BLCO, CA0717051076, Illustration mit AI erstellt.

Bausch + Lomb returned to quarterly profitability in the third quarter of 2026 and raised its full-year revenue outlook. Simply Wall St reported on November 8 that revenue reached 1.375 billion US dollars and net income was 32 million US dollars, compared with a loss a year earlier.

Bausch + Lomb stock traded at 18.95 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 11, 2026.

Higher guidance raises execution stakes

The company lifted its 2026 revenue range to 5.45 billion to 5.55 billion US dollars. The update strengthens the near-term case for growth across the eye-care portfolio, but the earnings improvement still needs to become consistent across the year.

Simply Wall St identified the Vision 27 efficiency program as a central catalyst. The analysis also highlighted prescription demand, premium surgical products, product mix and cost control as factors that could influence margins and cash generation.

Bausch + Lomb remained loss-making for the first nine months of 2026, according to the same analysis. That leaves profitability, debt reduction and execution against the higher revenue range as the main issues for investors following the shares.

Global eye health specialist

Bausch + Lomb is a global eye health company focused on protecting and enhancing sight throughout life, according to its investor relations website. Its business is built around eye health products and services for markets in the United States and internationally. The company trades on the New York Stock Exchange and the Toronto Stock Exchange.